Clinical Trials
470
38 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1997
Active, not recruiting
18
3.8%
Available
1
0.2%
Completed
222
47.2%
Enrolling By Invitation
11
2.3%
No Longer Available
2
0.4%
Not yet recruiting
9
1.9%
Recruiting
93
19.8%
Suspended
7
1.5%
Terminated
60
12.8%
Unknown
1
0.2%
Withdrawn
46
9.8%
No approval data available
- A Virginia physician woke to find a bat attempting to enter her mouth, prompting immediate emergency evaluation and rabies testing that ultimately returned negative. - Bats are the leading source of human rabies in the U.S., causing at least 7 out of 10 rabies fatalities, with two-thirds of annual rabies shots linked to bat exposure. - Experts advise that any direct physical contact with a bat, especially waking in a room with one, should be treated as a high-risk exposure requiring prompt medical assessment. - Post-exposure prophylaxis should begin as soon as possible after exposure, though rabies is considered a medical urgency rather than an emergency because infection spread takes days.
- The NCI-led Human Cancer Model Initiative published 665 validated patient-derived organoid models covering 25 cancer types in Nature, doubling the number of in vitro models available globally. - The CSHL-Northwell Health consortium contributed over 150 organoid models, including rare and underrepresented cancer subtypes such as endometrial and pediatric cancers. - Each model is annotated with comprehensive clinical data, treatment history, and advanced molecular profiles including DNA/RNA sequencing and epigenetic data. - The resource has already expanded the Cancer Dependency Map, enabling CRISPR-based discovery of new therapeutic vulnerabilities across diverse cancer subtypes.
- DYP688, a first-in-class antibody-drug conjugate targeting the Gq/11 pathway, demonstrated measurable anti-tumor activity in a Phase 1 trial for metastatic uveal melanoma published in Nature Medicine. - The trial achieved disease control in more than 80% of patients and cancer shrinkage in nearly 20%, with an exceptionally high degree of patient tolerability. - Unlike conventional ADCs carrying broadly toxic chemotherapy, DYP688 uses a Gq/11 inhibitor to selectively block the cancer's growth pathway while sparing healthy cells. - Despite Novartis halting development, the academic and patient communities recognize the drug's potential in a disease where patients face less than two years survival after metastasis.
- A brain-computer interface called the "double neural bypass" enabled a man paralyzed from the chest down to feed himself, drink from a cup, and regain the sensation of touch. - After 35 weeks of training, the patient's right arm strength increased 86% and left arm strength increased 62%, with lasting improvements persisting over two years. - The system routes movement signals from the brain to the limbs while simultaneously sending sensory feedback from pressure sensors back to the brain, completing a bidirectional circuit. - Researchers at the Feinstein Institutes for Medical Research developed a "cortical mirroring" technique that helped restore touch sensation in areas numb since the patient's 2020 accident.
- Brian S. Kim, MD, MTR, joins Northwell Health as its first chief biotechnology officer, overseeing biotechnology strategy and intellectual asset management at the Feinstein Institutes. - Dr. Kim's research contributed to two first-in-class FDA-approved therapies for atopic dermatitis and prurigo nodularis, and he has authored over 190 peer-reviewed publications. - He will advance bioelectronic medicine research, building on the Feinstein Institutes' pioneering work that led to the first FDA-approved vagus nerve stimulation implant for rheumatoid arthritis in 2025. - Kim co-founded Alys Pharmaceuticals, Neurommune Therapeutics, and Attu Therapeutics, and holds multiple patents on itch-centered technologies.
- Nicholas Hornstein, MD, PhD, highlights that positive ctDNA after colorectal cancer surgery signals an overwhelming likelihood of recurrence despite clean imaging and normal CEA. - The BESPOKE CRC study is reshaping clinical practice by examining ctDNA-guided adjuvant therapy decision-making for patients with stage II colorectal cancer. - Hornstein argues that current approved agents are insufficient to change disease trajectory, and the real clinical transformation will come from next-generation drugs now in phase 2 and 3 trials. - A c-MET inhibitor showed a 23% overall response rate in heavily pretreated metastatic colorectal cancer, while a RAS inhibitor plus PRMT5 inhibitor combination demonstrated over 90% disease control in pancreatic cancer.
- John M. Kane, MD, co-director of the Institute of Behavioral Science at the Feinstein Institutes, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society. - The award was presented during the SIRS Annual Conference in Florence, Italy, recognizing his decades-long contributions to schizophrenia understanding, treatment, and global patient outcomes. - Dr. Kane led the NIH-funded RAISE program that developed the NAVIGATE model of coordinated specialty care for first-episode psychosis patients and conducted groundbreaking research with clozapine for treatment-resistant schizophrenia. - Over his career, Dr. Kane has served as principal investigator on 24 NIH grants, authored more than 950 peer-reviewed papers, and held leadership roles in multiple psychiatric research societies.
- Scientists at Northwell Health's Feinstein Institutes have developed a paradigm-shifting drug discovery strategy that converts a previously harmful immune element into a therapeutic for sepsis and rheumatoid arthritis. - The research demonstrates that peptide P2-1, derived from an antibody epitope, effectively targets critical inflammatory pathways common to both life-threatening conditions. - This "disease-activated" treatment precisely targets overactive inflammatory pathways while preserving beneficial immune signals, offering improved safety over current broad immunosuppressive therapies. - The findings, published in Military Medical Research, represent over two decades of collaborative research aimed at addressing sepsis, which accounts for nearly 20 percent of global deaths.
- Northwell Health has officially opened the Center for Psychedelics Research and Treatment at Zucker Hillside Hospital, featuring a state-of-the-art laboratory with driving simulators and real-world social environments. - The center will conduct rigorous research on psychedelic compounds including psilocybin, MDMA, and cannabis for treating difficult conditions like social anxiety disorder, schizophrenia, and substance use disorders. - Initial research projects include a psilocybin clinical trial for social anxiety, an MDMA tolerability study in schizophrenia patients, and ecological assessment of naturalistic psychedelic use. - The facility plans to complete initial research within five years, launch federal-funded larger studies, and establish a clinical treatment program as regulatory approvals are achieved.
- Nitinotes has treated the first patient in its pivotal EASE Clinical Trial, evaluating the EndoZip automated suturing system for endoscopic sleeve gastroplasty at Lenox Hill Hospital in New York. - The randomized, multicenter study will compare automated ESG to manual suturing techniques across up to 184 patients at 10 sites in the US and Europe over 12 months. - This IDE study represents the first randomized comparison of automated versus manual ESG approaches and is designed to support future FDA regulatory submission. - The milestone follows recent CE Mark approval for EndoZip, enabling commercial launch in European markets while addressing the treatment gap between GLP-1 therapy and bariatric surgery.
